{
  "query_term": "IMBRUVICA (ibrutinib)",
  "total_count": 441,
  "returned": 20,
  "kept": 4,
  "studies": [
    {
      "nct_id": "NCT02315326",
      "title": "A Phase I/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)",
      "overall_status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)",
        "Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)"
      ],
      "lead_sponsor": "Memorial Sloan Kettering Cancer Center",
      "collaborators": [
        "Pharmacyclics LLC.",
        "Janssen Biotech, Inc."
      ],
      "interventions": [
        "Ibrutinib",
        "HD- Methotrexate (MTX)",
        "Rituximab + HD- Methotrexate (MTX)",
        "procarbazine"
      ],
      "last_update": "2025-07-01",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT02315326"
    },
    {
      "nct_id": "NCT01236391",
      "title": "Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma",
      "overall_status": "COMPLETED",
      "phase": "Phase 2",
      "conditions": [
        "Mantle Cell Lymphoma"
      ],
      "lead_sponsor": "Pharmacyclics LLC.",
      "collaborators": [
        "Janssen Pharmaceuticals"
      ],
      "interventions": [
        "PCI-32765"
      ],
      "last_update": "2015-08-28",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT01236391"
    },
    {
      "nct_id": "NCT04010968",
      "title": "Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia: a Randomized Phase II Trial Comparing FCR and a Chemo-free Combination of Venetoclax and Ibrutinib. A FILO Study",
      "overall_status": "COMPLETED",
      "phase": "Phase 2",
      "conditions": [
        "Intermediate Risk Chronic Lymphocytic Leukemia",
        "Fit Patients",
        "Risk-Adapted and MRD-Driven Strategy"
      ],
      "lead_sponsor": "French Innovative Leukemia Organisation",
      "collaborators": [
        "AbbVie",
        "Janssen-Cilag Ltd."
      ],
      "interventions": [
        "venetoclax and ibrutinib (I+VEN)",
        "FCR"
      ],
      "last_update": "2025-11-26",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04010968"
    },
    {
      "nct_id": "NCT01820936",
      "title": "Open-Label, Randomized, 4-Way Crossover Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765",
      "overall_status": "COMPLETED",
      "phase": "Phase 1",
      "conditions": [
        "Healthy Volunteers"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [
        "Pharmacyclics LLC."
      ],
      "interventions": [
        "Sequence 1: PCI-32765",
        "Sequence 2: PCI-32765",
        "Sequence 3: PCI-32765",
        "Sequence 4: PCI-32765",
        "Sequence 5: PCI-32765"
      ],
      "last_update": "2014-07-15",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT01820936"
    }
  ]
}